Physician profile
Can Ilyas
NPI 1770625410
$1,079.50
in general payments reported to CMS, 2019-2025
19 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.63 · 2020: $81.05 · 2021: $326 · 2022: $283 · 2023: $90.17 · 2024: $108 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $332 · Education: $43.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $331.55 |
| Education | $43.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $163.68 | 2020-2023 | Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $140.96 | 2022-2024 | Opdivo |
| Abbvie INC. | $135.36 | 2024-2025 | |
| Celgene Corporation | $124.99 | 2021 | |
| Epizyme, INC. | $99.95 | 2021 | |
| Astellas Pharma US INC | $66.66 | 2021-2025 | Vyloy |
| Seagen INC. | $57.25 | 2021-2023 | Adcetris |
| Rigel Pharmaceuticals, INC. | $39.62 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $32.18 | 2025 | Enhertu |
| Daiichi Sankyo INC. | $31.64 | 2024 | Enhertu |
| Incyte Corporation | $28.65 | 2021-2022 | |
| Pfizer INC. | $28.49 | 2019-2020 | |
| Genentech USA, INC. | $26.33 | 2023 | Phesgo, Tecentriq, Venclexta |
| Amgen INC. | $22.57 | 2022 | |
| Janssen Pharmaceuticals, INC | $22.00 | 2024 | Rybrevant |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $19.67 | 2025 | |
| Merck Sharp & Dohme LLC | $15.61 | 2020 | |
| Genzyme Corporation | $11.97 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Can Ilyas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.